Evidence map›Paper›PMID 33668818›Full record

ArticleInternational journal of environmental research and public health2021

Indol-3-Carbinol and Quercetin Ameliorate Chronic DSS-Induced Colitis in C57BL/6 Mice by AhR-Mediated Anti-Inflammatory Mechanisms.

Sina Riemschneider, Maximilian Hoffmann, Ulla Slanina, Klaus Weber, Sunna Hauschildt, Jörg Lehmann

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 93 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Elucidating the Potential Mechanism of Ulcerative Colitis Amelioration byCombinatorial chemistry & high throughput screening · 2026
    Article
  8. Article
  9. CD126Orphanet journal of rare diseases · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Therapeutic potential ofFrontiers in pharmacology · 2025
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Sina RiemschneiderDepartment of Therapy Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Maximilian HoffmannDepartment of Therapy Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Ulla SlaninaDepartment of Therapy Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Klaus WeberAnaPath GmbH, CH-4410 Liestal, Switzerland.
Sunna HauschildtFaculty of Life Sciences, University of Leipzig, 04103 Leipzig, Germany.
Jörg LehmannDepartment of Therapy Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Fraunhofer Institute for Cell Therapy and Immunology · DEFraunhofer Research Institution for Materials Recycling and Resource Strategies IWKS · DELeipzig University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, are multifactorial inflammatory disorders of the gastrointestinal tract, characterised by abdominal cramps, bloody diarrhoea, and anaemia. Standard therapies, including corticosteroids or biologicals, often induce severe side effects, or patients may develop resistance to those therapies. Thus, new therapeutic options for IBD are urgently needed. This study investigates the therapeutic efficacy and safety of two plant-derived ligands of the aryl hydrocarbon receptor (AhR), quercetin (Q), and indol-3-carbinol (I3C), using a translationally relevant mouse model of IBD. Q and I3C are administered by gavage to C57BL/6 wild-type or C57BL/6

Indexed as

ColitisReceptors, Aryl HydrocarbonAnimalsAnti-Inflammatory AgentsDextran SulfateDisease Models, AnimalHumansMethanolMiceMice, Inbred C57BLQuercetinAnti-Inflammatory AgentsDextran SulfateMethanolQuercetinReceptors, Aryl Hydrocarbonaryl hydrocarbon receptor (AhR)chronic colitisindol-3-carbinol (I3C)inflammatory bowel disease (IBD)mouse modelphytotherapyquercetin

Identifiers

PMID33668818
PMCPMC7956562
OpenAlexW3133204063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.